The DOI matches its Crossref record.
The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes.
Abstract
FK506, a neutral macrolide with immunosuppressive properties, was shown to selectively and rapidly inhibit the accumulation of IL-2 mRNA, as well as the mRNAs of other early (E) phase T cell activation genes such as IL-3, IL-4, GM-CSF, TNF alpha, IFN-gamma, and c-myc in activated human peripheral blood T cells. The activity of FK506, when compared to Cyclosporin A, another immunosuppressant, was 10 to 100x more potent in its ability to inhibit IL-2 mRNA synthesis. FK506 inhibited IL-2 mRNA accumulation in Con A, Con A plus PMA, Ionomycin plus PMA, anti-CD3, and anti-CD3 plus PMA activated T cells. Transcripts from other T cell gene classes such as the immediate early (IE) phase gene, c-fos, the late phase (L) genes, transferrin receptor, IL-2R alpha-chain, and TNF-beta, and the constitutive class genes glyceraldehyde-3-phosphate dehydrogenase and class I MHC HLA-B7 were not affected by FK506. The macrolide Rapamycin, which is structurally related to FK506, had no inhibitory effect on IE, E, L, or constitutive class mRNAs, but it appeared to increase the levels of the E-phase transcripts that were inhibited in FK506 treated T cells. The effect of FK506 on inducible genes in non-T and non-lymphoid human cells was studied in LPS-induced monocytes and PMA or IL-1 activated synovial fibroblasts. FK506 did not affect expression of the mRNAs for IL-1 alpha or IL-1 beta in human monocytes, or of stromelysin, collagenase, or TIMP in synovial fibroblasts. Nuclear run-off transcription studies indicate that FK506 inhibits transcription of the IL-2 gene. These studies suggest that Cyclosporin A and FK506 may effect a common early event in the T cell activation pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116
TRANSCRIPTION FACTORS OF THE NFAT FAMILY:Regulation and Function
Rao, A., Luo, C., & Hogan, P. G. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.707 · Cited by 2,603
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands
Schreiber, S. L. (1991) · Science · doi:10.1126/science.1702904 · Cited by 1,494
A T cell-dependent experimental liver injury in mice inducible by concanavalin A.
Tiegs, G., Hentschel, J., & Wendel, A. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115836 · Cited by 1,074
Siekierka, J. J., Hung, S. H. Y., Poe, M., Lin, C. S., & Sigal, N. H. (1989) · Nature · doi:10.1038/341755a0 · Cited by 1,010
Self-citationJNK is involved in signal integration during costimulation of T lymphocytes
Su, B., Jacinto, E., Hibi, M., Kallunki, T., Karin, M., & Ben-Neriah, Y. (1994) · Cell · doi:10.1016/0092-8674(94)90056-6 · Cited by 906
X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex
Griffith, J. P., Kim, J. L., Kim, E. E., Sintchak, M. D., Thomson, J. A., Fitzgibbon, M. J., Fleming, M. A., Caron, P. R., Hsiao, K., & Navia, M. A. (1995) · Cell · doi:10.1016/0092-8674(95)90439-5 · Cited by 834
Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A.
Fruman, D. A., Klee, C. B., Bierer, B. E., & Burakoff, S. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3686 · Cited by 823
Bierer, B. E., Mattila, P. S., Standaert, R. F., Herzenberg, L. A., Burakoff, S. J., Crabtree, G., & Schreiber, S. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9231 · Cited by 696
IMMUNOPHARMACOLOGY OF RAPAMYCIN
Abraham, R. T., & Wiederrecht, G. J. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.483 · Cited by 653
Transcriptional regulation of the IL-2 gene
Jain, J. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80107-3 · Cited by 565
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481
Friedman, J., & Weissman, I. (1991) · Cell · doi:10.1016/0092-8674(91)90123-g · Cited by 395
Current Concepts in the Etiology and Treatment of Behçet Disease
Evereklioglu, C. (2005) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2005.04.009 · Cited by 393
Mechanism of action of the immunosuppressant rapamycin
Dumont, F. J., & Su, Q. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02233-3 · Cited by 358
Self-citationPeters, D. H., Fitton, A., Plosker, G. L., & Faulds, D. (1993) · Drugs · doi:10.2165/00003495-199346040-00009 · Cited by 356
The Mechanism of Action of FK‐506 and Cyclosporin A
WIEDERRECHT, G., LAM, E., HUNG, S., MARTIN, M., & SIGAL, N. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb17137.x · Cited by 350
The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes.
Mattila, P. S., Ullman, K. S., Fiering, S., Emmel, E. A., McCutcheon, M., Crabtree, G. R., & Herzenberg, L. A. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07893.x · Cited by 349
Shaw, K. T., Ho, A. M., Raghavan, A., Kim, J., Jain, J., Park, J., Sharma, S., Rao, A., & Hogan, P. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11205 · Cited by 345
Peptidylproline cis‐trans‐isomerases: immunophilins
GALAT, A. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb18189.x · Cited by 343
Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B.
Frantz, B., Nordby, E. C., Bren, G., Steffan, N., Paya, C. V., Kincaid, R. L., Tocci, M. J., O'Keefe, S. J., & O'Neill, E. A. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06329.x · Cited by 334
Self-citationCurrent Concepts in the Etiology and Treatment of Behçet Disease
Androudi, S. (2006) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2005.12.006 · Cited by 333
Molecular cloning and overexpression of the human FK506-binding protein FKBP
Standaert, R. F., Galat, A., Verdine, G. L., & Schreiber, S. L. (1990) · Nature · doi:10.1038/346671a0 · Cited by 312
Cafferkey, R., Young, P. R., McLaughlin, M. M., Bergsma, D. J., Koltin, Y., Sathe, G. M., Faucette, L., Eng, W. K., Johnson, R. K., & Livi, G. P. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6012 · Cited by 309
Peptidyl‐Prolyl cis/trans Isomerases and Their Effectors
Fischer, G. (1994) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199414151 · Cited by 308
Calcineurin Binds the Transcription Factor NFAT1 and Reversibly Regulates Its Activity
Loh, C., Shaw, K. T.-Y., Carew, J., Viola, J. P. B., Luo, C., Perrino, B. A., & Rao, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.18.10884 · Cited by 299
Heitman, J., Movva, N. R., Hiestand, P. C., & Hall, M. N. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.5.1948 · Cited by 294
Stamnes, M. A., Shieh, B.-H., Chuman, L., Harris, G. L., & Zuker, C. S. (1991) · Cell · doi:10.1016/0092-8674(91)90156-s · Cited by 263
Reitamo, S., Rustin, M., Ruzicka, T., Cambazard, F., Kalimo, K., Friedmann, P. S., Schoepf, E., Lahfa, M., Diepgen, T. L., Judodihardjo, H., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121832 · Cited by 258
Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides
Morris, R. E. (1992) · Transplantation Reviews · doi:10.1016/s0955-470x(10)80014-x · Cited by 253
Rapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252
Dumont, F. J., Staruch, M. J., Koprak, S. L., Siekierka, J. J., Lin, C. S., Harrison, R., Sewell, T., Kindt, V. M., Beattie, T. R., & Wyvratt, M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.3.751 · Cited by 250
Self-citationHuyghe, E., Zairi, A., Nohra, J., Kamar, N., Plante, P., & Rostaing, L. (2007) · Transplant International · doi:10.1111/j.1432-2277.2006.00423.x · Cited by 159
Wiederrecht, G., Hung, S., Chan, H. K., Marcy, A., Martin, M., Calaycay, J., Boulton, D., Sigal, N., Kincaid, R. L., & Siekierka, J. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36676-1 · Cited by 115
Ong, S., Levy, R. D., Yee, J., Partovi, N., Churg, A., Roméo, P., Chalaoui, J., Nador, R., Wright, A., Manganas, H., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0727-0 · Cited by 18
Metadata
- Authors
- Tocci, M. J., Matkovich, D. A., Collier, K. A., Kwok, P., Dumont, F., Lin, S., Degudicibus, S., Siekierka, J. J., Chin, J., & Hutchinson, N. I.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1989-07
- Volume
- 143
- Issue
- 2
- Pages
- 718-726
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1562075782
- Cited by
- 662
- References
- 0
- FWCI
- 17.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.